Literature DB >> 22390216

Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.

Marie Stiborová1, Radek Indra, Michaela Moserová, Věra Cerná, Martina Rupertová, Václav Martínek, Tomáš Eckschlager, René Kizek, Eva Frei.   

Abstract

The antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (P450)- and/or peroxidase-mediated activation in target tissues. The P450 3A4 enzyme oxidizes ellipticine to five metabolites, mainly to 13-hydroxy- and 12-hydroxyellipticine, the metabolites responsible for the formation of ellipticine-13-ylium and ellipticine-12-ylium ions that generate covalent DNA adducts. Cytochrome b(5) alters the ratio of ellipticine metabolites formed by P450 3A4. While the amounts of the detoxication metabolites (7-hydroxy- and 9-hydroxyellipticine) were not changed with added cytochrome b(5), 12-hydroxy- and 13-hydroxyellipticine, and ellipticine N(2)-oxide increased considerably. The P450 3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b(5), while apo-cytochrome b(5) without heme or Mn-cytochrome b(5) had no such effect. The change in amounts of metabolites resulted in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. The amounts of 13-hydroxy- and 12-hydroxyellipticine formed by P450 3A4 were similar, but more than 7-fold higher levels of the adduct were formed by 13-hydroxyellipticine than by 12-hydroxyellipticine. The higher susceptibility of 13-hydroxyellipticine toward heterolytic dissociation to ellipticine-13-ylium in comparison to dissociation of 12-hydroxyellipticine to ellipticine-12-ylium, determined by quantum chemical calculations, explains this phenomenon. The amounts of the 13-hydroxyellipticine-derived DNA adduct significantly increased upon reaction of 13-hydroxyellipticine with either 3'-phosphoadenosine-5'-phosphosulfate or acetyl-CoA catalyzed by human sulfotransferases 1A1, 1A2, 1A3, and 2A1, or N,O-acetyltransferases 1 and 2. The calculated reaction free energies of heterolysis of the sulfate and acetate esters are by 10-17 kcal/mol more favorable than the energy of hydrolysis of 13-hydroxyellipticine, which could explain the experimental data.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22390216     DOI: 10.1021/tx3000335

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  13 in total

1.  Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling.

Authors:  Marie Stiborova
Journal:  J Vis Exp       Date:  2018-03-20       Impact factor: 1.355

Review 2.  The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.

Authors:  Marie Stiborová; Věra Černá; Michaela Moserová; Iveta Mrízová; Volker M Arlt; Eva Frei
Journal:  Int J Mol Sci       Date:  2014-12-25       Impact factor: 5.923

3.  Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study.

Authors:  Marie Stiborova; Zuzana Manhartova; Petr Hodek; Vojtech Adam; Rene Kizek; Eva Frei
Journal:  Sensors (Basel)       Date:  2014-12-03       Impact factor: 3.576

4.  NADH:Cytochrome b5 Reductase and Cytochrome b5 Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene.

Authors:  Marie Stiborová; Radek Indra; Michaela Moserová; Eva Frei; Heinz H Schmeiser; Klaus Kopka; David H Phillips; Volker M Arlt
Journal:  Chem Res Toxicol       Date:  2016-07-20       Impact factor: 3.739

5.  A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.

Authors:  Marie Stiborová; František Bárta; Kateřina Levová; Petr Hodek; Heinz H Schmeiser; Volker M Arlt; Václav Martínek
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

6.  Induced expression of microsomal cytochrome b5 determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I).

Authors:  Marie Stiborová; Michaela Moserová; Iveta Mrízová; Helena Dračínská; Václav Martínek; Radek Indra; Eva Frei; Vojtěch Adam; René Kizek; Heinz H Schmeiser; Kateřina Kubáčková; Volker M Arlt
Journal:  Monatsh Chem       Date:  2016-01-12       Impact factor: 1.451

7.  Heterologous expression of human cytochrome P450 2S1 in Escherichia coli and investigation of its role in metabolism of benzo[a]pyrene and ellipticine.

Authors:  Iveta Mrízová; Michaela Moserová; Jan Milichovský; Miroslav Šulc; René Kizek; Kateřina Kubáčková; Volker M Arlt; Marie Stiborová
Journal:  Monatsh Chem       Date:  2016-03-30       Impact factor: 1.451

8.  NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[a]pyrene catalyzed with rat hepatic microsomes and cytochrome P450 1A1.

Authors:  Marie Stiborová; Radek Indra; Michaela Moserová; Miroslav Šulc; Petr Hodek; Eva Frei; Heinz H Schmeiser; Volker M Arlt
Journal:  Monatsh Chem       Date:  2016-03-09       Impact factor: 1.451

9.  Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems.

Authors:  Marie Stiborová; Radek Indra; Michaela Moserová; Lucie Bořek-Dohalská; Petr Hodek; Eva Frei; Klaus Kopka; Heinz H Schmeiser; Volker M Arlt
Journal:  Monatsh Chem       Date:  2017-07-10       Impact factor: 1.451

10.  Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine.

Authors:  Marie Stiborová; Radek Indra; Eva Frei; Kateřina Kopečková; Heinz H Schmeiser; Tomáš Eckschlager; Vojtěch Adam; Zbyněk Heger; Volker M Arlt; Václav Martínek
Journal:  Monatsh Chem       Date:  2017-07-04       Impact factor: 1.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.